# Lesson 5 — Sexual and Reproductive Health (v3 expanded)

*Companion-podcast transcript • Sarah & Kiffer*  
*~5,300 words • ~29 min audio*

---

**Sarah:** Welcome back to Office Hours. I'm Sarah.

**Kiffer:** And I'm Kiffer. Today we're on Lesson 5 — sexual and reproductive health. And before we get into the substance I want to flag something the module says up front. This is the area where public health most directly meets politics, religion, gender, and human rights. The science doesn't sit in a neutral space. Every major milestone in this field has carried political and moral content beyond what its immediate public health framing suggested.

**Sarah:** That's the frame. Four sections. Maternal mortality. Birth control and reproductive autonomy. STIs, syphilis, and Tuskegee. And then H I V and the activist transformation of clinical research.

**Kiffer:** And as a connection point — we touched on Tuskegee briefly last lesson when we did Belmont. We touched on H I V last lesson in the pandemics section. This lesson goes deeper on both. The arc is denser and more morally complicated than what we've covered so far.

**Sarah:** Let's start with maternal mortality. The framing the module uses is striking. The fact that maternal mortality is no longer routine in industrialized countries is one of public health's largest achievements. The fact that it remains stubbornly inequitable, both globally and within wealthy countries, is one of its largest failures.

**Kiffer:** Right. And we already met Semmelweis in Lesson 3 for hand hygiene. Worth meeting him again from a maternal mortality lens. Vienna General Hospital, eighteen forties. Two maternity clinics. The First Clinic, physician and medical-student staffed, was running maternal mortality from puerperal fever at about eighteen percent. The Second Clinic, midwife-staffed, ran at about two percent.

**Sarah:** And the disparity was so large that —

**Kiffer:** Pregnant women in Vienna would beg to be admitted to the Second Clinic. Some of them, faced with admission to the First Clinic, gave birth in the street instead. And had lower mortality than those admitted to the physician-staffed clinic. That's the level of harm we're talking about. Then Semmelweis figures out the cause, institutes the hand-washing protocol with chlorinated lime water, and mortality on the First Clinic drops to match the Second.

**Sarah:** And the module makes a sharper point through the maternal-mortality lens.

**Kiffer:** Yeah. From a hand-hygiene lens, Semmelweis is a parable about resistance to evidence in medicine. From a maternal-mortality lens, it's also a parable about what happens when a problem affects only women. Maternal mortality at eighteen percent per delivery would have been treated as a national emergency if it had affected any other patient population. It was treated as background noise because the affected population was women, mostly poor, in hospitals that catered primarily to those who had no alternative. The pattern of underweighting maternal mortality is unfortunately not extinct.

**Sarah:** Then the twentieth-century decline.

**Kiffer:** Maternal mortality in industrialized countries fell roughly a hundred-fold between 1900 and 2000. Driven by a combination of interventions. Antisepsis and aseptic technique — descendants of Lister and Semmelweis — dramatically reduced infection. Antibiotics, sulfa drugs from 1935 and penicillin from 1944, made survivable the infections that did occur. Blood transfusion, made routinely safe through blood typing that began with Karl Landsteiner's nineteen-oh-one work, made survivable postpartum hemorrhage that had previously been uniformly fatal. Anaesthesia made cesarean section a survivable procedure rather than a desperate last resort. Prenatal care emerged in the early twentieth century. Skilled birth attendance became near-universal by mid-century.

**Sarah:** And the numbers.

**Kiffer:** In the U K, from approximately four hundred per hundred thousand live births in 1900 to approximately nine per hundred thousand by 2000. In the U S, similar trajectory, slightly different shape — steeper through mid-century, plateaued earlier. Canadian maternal mortality reached approximately six per hundred thousand by 2000. A population health gain of roughly two orders of magnitude in a century. Few public health interventions can claim a comparable record.

**Sarah:** And globally the picture is much more uneven.

**Kiffer:** Maternal mortality in some low-income countries remains above five hundred per hundred thousand live births. Close to the historical baseline. The Millennium Development Goal target of reducing global maternal mortality by seventy-five percent between 1990 and 2015 was substantially missed. The Sustainable Development Goal target — below seventy per hundred thousand by 2030 — is also unlikely to be met globally. The interventions that work are well-characterized. Skilled birth attendance. Emergency obstetric care. Family planning. Prenatal care. The political and economic conditions to deliver them at scale are the limiting constraint.

**Sarah:** Then the U S story. Which is the strangest part of this section.

**Kiffer:** The maternal mortality paradox. Starting around 2000, the U S maternal mortality rate began to rise. Slowly at first, then more dramatically. By 2020 it had reached approximately twenty-four per hundred thousand live births, having tripled from its mid-nineties baseline. The COVID-nineteen pandemic accelerated it. By 2021 the official U S rate was approximately thirty-three per hundred thousand. Highest in any high-income country. The U S is the only high-income country with rising maternal mortality in the twenty-first century.

**Sarah:** That's a very dark statistic.

**Kiffer:** And the reasons are debated. Several contributors consistently identified. Rising chronic conditions among pregnant women — obesity, hypertension, diabetes. Rising maternal age at first birth. Access to care more fragmented and unequal under the U S health insurance system. Postpartum care — the period when many maternal deaths occur — particularly underserved. And racial and structural barriers to high-quality maternity care not adequately addressed. Some of the apparent rise is improved death-certificate coding, but only a part. The substantive rise is real.

**Sarah:** And the racial disparity.

**Kiffer:** Sharp. Black women in the U S have approximately three times the maternal mortality of white women. Approximately seventy per hundred thousand versus approximately twenty-seven per hundred thousand in 2021. The disparity is not explained by income, education, or insurance status. Controlling for those reduces but does not eliminate the gap. Educated, insured Black women have higher maternal mortality than uninsured, less-educated white women.

**Sarah:** And the interpretation is —

**Kiffer:** Most often interpreted as reflecting structural and interpersonal racism in healthcare. Manifested as dismissal of pain, delays in diagnosis, communication failures, assumptions about the patient's likely behavior and adherence. Serena Williams's near-fatal postpartum experience in 2017, which she's discussed publicly, has been pointed to as a high-profile case of how even resourced, prominent Black women can face delays in care that lower-resource Black women face routinely.

**Sarah:** And in Canada.

**Kiffer:** Indigenous women in Canada experience approximately two times the maternal mortality of non-Indigenous women. Similar attributions to structural racism, jurisdictional confusion about responsibility for Indigenous healthcare, and the legacy of colonial trauma affecting both health status and trust in the health system. The Native Women's Association of Canada has been advocating for systemic reform. Some progress — the First Nations Health Authority's prenatal program in B C, for instance — but persistent gaps.

**Sarah:** And the contemporary policy response in the U S.

**Kiffer:** Several states have introduced maternal mortality review committees — multidisciplinary panels that review each maternal death in detail and identify preventable factors. The findings across jurisdictions are consistent. Roughly eighty percent of U S maternal deaths are deemed preventable. The major preventable causes are delayed recognition and treatment of postpartum hemorrhage, hypertensive emergencies, cardiovascular events, mental health crises, and substance use overdoses. And approximately thirty percent of U S maternal deaths occur during the late postpartum period — between six weeks and one year after delivery — which is traditionally outside the focus of obstetric care.

**Sarah:** And reforms that look promising.

**Kiffer:** Extended postpartum Medicaid coverage. Most states have extended from sixty days to twelve months postpartum since 2021. Standardized postpartum care visits with mental health and cardiovascular screening. Community-based doula programs. Improved infrastructure for hospital-based emergency obstetric care. Whether these reverse the trend remains to be seen. And in Canada the Maternal Health Strategy is under development as of 2026. Mental health-related maternal deaths, including suicide, have risen in some jurisdictions. The opioid crisis has produced an increase in maternal deaths from drug toxicity in pregnancy and postpartum.

**Sarah:** Okay. Section two. Birth control and reproductive autonomy.

**Kiffer:** And this section is uncomfortable to teach honestly because the central figure is genuinely complicated. Margaret Sanger.

**Sarah:** Walk us through her.

**Kiffer:** Sanger, eighteen seventy-nine to nineteen sixty-six. Most associated with the modern birth control movement in North America. Trained as a nurse in early twentieth-century New York. Worked with poor immigrant communities. Saw the consequences of unplanned and closely spaced pregnancies firsthand. Her sister died of complications from an unsafe abortion. Sanger came to view contraception as essential to women's health and freedom and committed her career to making it legal and accessible.

**Sarah:** And her advocacy was —

**Kiffer:** Not subtle. She founded the first U S birth control clinic in Brooklyn in October 1916 and was arrested within nine days under the 1873 Comstock Act, which prohibited the distribution of contraceptive information or materials. She was repeatedly arrested and jailed in the following years. The organization she founded — initially the American Birth Control League in 1921, later renamed Planned Parenthood Federation of America in 1942 — has been one of the most consequential reproductive health organizations in U S history. By the time Sanger died in 1966, contraception was legal across the United States.

**Sarah:** And the legacy is contested.

**Kiffer:** Genuinely. She made contraception a public good and her advocacy was effective. She also expressed views — particularly in the nineteen-twenties and thirties — that aligned with the eugenics movement of the era. She wrote approvingly of differential birth rates among, in her words, desirable and undesirable populations. She gave a 1926 speech to a women's auxiliary of the Ku Klux Klan. She supported sterilization in some circumstances. These views were not peripheral. They were part of how she argued for birth control in some of her writing.

**Sarah:** And Planned Parenthood publicly disavowed her eugenic views in 2020.

**Kiffer:** Removed her name from the New York City Planned Parenthood center. The careful contemporary reading treats both as true and distinct facts about the same person. Sanger transformed reproductive health and helped make contraception a public good — a benefit primarily to poor and working-class women. She also expressed views that were racist by contemporary standards and harmful in their implications. The complexity is real and is part of the history students should know.

**Sarah:** Then the Pill.

**Kiffer:** Enovid — norethynodrel plus mestranol — was developed by chemists at G D Searle pharmaceutical company in the nineteen-fifties. Building on work by the Mexican chemist Carl Djerassi, who had synthesized the first oral progestin compound in 1951. The clinical trials that led to F D A approval were conducted in part in Puerto Rico in 1956. Setting chosen partly because of permissive regulation and partly because of the desire to test in non-white populations before broader release.

**Sarah:** And the ethical record on those trials.

**Kiffer:** Falls far short of modern standards. Informed-consent procedures inadequate. Several women died during the trials of complications that may or may not have been related to the drug. The decision to proceed to F D A approval despite these deaths has been criticized retrospectively. Enovid was approved by the F D A in 1960, initially for menstrual regulation. Contraception became the rapid de facto application. By 1965, approximately six and a half million American women were taking the Pill. By 1967, approximately twelve and a half million women globally. Diffusion in Canada and elsewhere followed quickly.

**Sarah:** And the social consequences are documented in a really clean piece of work by Claudia Goldin and Lawrence Katz.

**Kiffer:** Yeah. Economists at Harvard. They published a series of papers in the two thousands that documented the causal effects of Pill availability on women's economic and educational trajectories. They used state-by-state variation in the age at which women could legally access the Pill — which varied across U S states through the late sixties and early seventies — as a natural experiment.

**Sarah:** Connection to last lesson — that's the kind of natural experiment methodology Snow pioneered.

**Kiffer:** Same logical structure. And Goldin and Katz showed that Pill access produced substantial increases in women's college attendance, professional school enrollment, age at first marriage, age at first birth, and labor force participation. The effects were causal, driven by the variation in the legal age. The design is essentially a regression discontinuity in time, exploiting the sharp policy change. The methodology is now standard in policy evaluation. The empirical findings are among the most cited causal claims in social science. Goldin won the Nobel Prize in Economics in 2023 partly for this body of work.

**Sarah:** And one thing the module is careful to do — Pill effects aren't only social, they're health.

**Kiffer:** Right. The reflection prompt actually asks this directly. Take women's labor force participation. Higher participation means independent income. Which means independent access to housing, food, and healthcare — all direct determinants of health. It means an exit option from violent or unhealthy relationships. Lower fertility means lower maternal mortality exposure. Access to employer-provided health benefits where those matter. The artificial separation between social and health outcomes is one of the things this whole course is trying to dissolve.

**Sarah:** And then long-acting reversible contraceptives. The LARCs.

**Kiffer:** I U Ds, implants. One-year failure rates of about zero point one to zero point five percent. Substantially higher real-world effectiveness than the Pill, which is seven to nine percent failure in typical use. Because LARCs don't depend on user compliance. Once they're in place, they work. Public health interest in LARCs has grown because the failure-rate difference matters for population-level outcomes.

**Sarah:** And the Dobbs decision in 2022.

**Kiffer:** Overturned Roe v. Wade in the United States. Returned abortion regulation to state-by-state legislation. Approximately fourteen U S states have severely restricted abortion since. The public health consequences are being tracked in real time. Documented increases in maternal morbidity in restricting states. Maternal mortality effects beginning to emerge in 2024 to '25 data. Several states have seen obstetrician departures, particularly from rural areas, citing legal uncertainty about high-risk obstetric care.

**Sarah:** And Canadian access.

**Kiffer:** Broadly available but with persistent rural and remote gaps. Globally, the post-pandemic reduction in international family-planning funding has produced measurable increases in unintended pregnancy and maternal mortality in some low-income countries. Telehealth-mediated reproductive care has expanded substantially. Medication abortion, contraceptive counseling, S T I testing — all increasingly available through telehealth. Potential to address access gaps in rural and remote communities, including in Canada.

**Sarah:** Okay. Section three. S T Is, syphilis, and Tuskegee.

**Kiffer:** And we touched on Tuskegee in Lesson 1 in the context of research integrity. This section goes through it carefully because the consequences continue to shape contemporary public health.

**Sarah:** Walk us through the study.

**Kiffer:** Beginning in 1932, the U S Public Health Service enrolled approximately six hundred African American men in Macon County, Alabama. Three hundred ninety-nine with latent syphilis, two hundred one without. In a research study purportedly designed to observe the natural course of untreated syphilis. The men were poor sharecroppers, most with limited literacy. They were told they were being treated for, quote, bad blood. A vague folk diagnosis. They were given free physical examinations, transportation to clinics, meals on examination days, and free burial insurance — which was the actual research mechanism for obtaining autopsies. They were not told they had syphilis. They were not told the study's purpose was observation rather than treatment.

**Sarah:** And the study continued for forty years.

**Kiffer:** Forty years. In 1947, penicillin became the standard of care for syphilis treatment. Single course of injections, reliably cures the disease in nearly all cases. The Tuskegee investigators deliberately withheld penicillin from the participants. They also worked to ensure participants would not receive treatment from other sources. When the men were drafted into World War Two military service, the Public Health Service intervened to exempt them from the routine syphilis screening and treatment provided to other military personnel. As local health departments began treating syphilis cases in Alabama after the war, the Public Health Service worked to identify Tuskegee participants and ensure they weren't included.

**Sarah:** And it wasn't secret.

**Kiffer:** No. It was published in medical journals throughout its forty-year run. Hundreds of physicians and public health officials were aware of it. None intervened. The participants and their wives — some of whom became infected after the men were enrolled, since the men were not told to use protection — were not informed of their condition.

**Sarah:** And it ended in 1972.

**Kiffer:** November 1972. After Jean Heller of the Associated Press published an exposé based on whistleblower disclosures from Peter Buxtun, a Public Health Service investigator who had attempted internally for years to stop the study. By the time the study was terminated, dozens of the original participants had died of syphilis. Many had infected their wives. At least nineteen children had been born with congenital syphilis. The U S government formally apologized in 1997 when President Clinton invited surviving participants to the White House. A class-action settlement provided modest financial compensation to participants and their families.

**Sarah:** And the regulatory response.

**Kiffer:** Unprecedented. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research was established by federal law in 1974. Worked for four years on what became the 1979 Belmont Report. Foundational document of modern research ethics. Three core principles. Respect for persons — autonomy, informed consent. Beneficence — maximizing benefits and minimizing harm. And justice — fair distribution of research burdens and benefits.

**Sarah:** And the institutional machinery that flowed from it.

**Kiffer:** Institutional Review Boards in the U S. Research Ethics Boards in Canada. Analogous structures in most countries with substantial biomedical research. Every federally funded human-subjects research project must be reviewed and approved before enrollment can begin. Reviews consider consent process, risk-benefit balance, subject selection, data security, many other dimensions. Continuing review is required. Adverse event reporting requirements ensure that emerging risks are identified.

**Sarah:** And in Canada, the T C P S two.

**Kiffer:** Tri-Council Policy Statement on Ethical Conduct for Research Involving Humans. Second edition. Most recently updated in 2022. Applies to research funded by the three federal research agencies — C I H R, N S E R C, and S S H R C. Chapter 9 specifically addresses research with First Nations, Inuit, and Métis peoples. Drawing on the O C A P principles. We've touched on O C A P a couple of times now. Ownership, Control, Access, Possession. The framework for Indigenous data sovereignty in Canada.

**Sarah:** And the module is honest that the modern ethics infrastructure prevents Tuskegee-style studies but doesn't fully address contemporary challenges.

**Kiffer:** That's right. Tuskegee was conducted by a respectable federal agency, by well-credentialed scientists, with the knowledge of hundreds of physicians and public health officials. It continued for two decades after the treatment was discovered. The conditions that produced it — racism, paternalism, the assumption that some lives count less, institutional inertia, professional silence — were not unique to that study or that era and have not been eliminated by post-Belmont infrastructure.

**Sarah:** And the downstream effects on trust.

**Kiffer:** Real and consequential. Survey data has consistently shown elevated medical mistrust among Black Americans compared with white Americans. The mistrust contributes to lower rates of organ donation, lower participation in clinical trials, and lower uptake of preventive services. The COVID-nineteen vaccination campaign in Black communities required substantial additional outreach and partnership work specifically because of this history. Public health workers today still encounter the legacy of Tuskegee in their work.

**Sarah:** And Canada has its own analogous reckonings.

**Kiffer:** The Indian residential school system, federal government from the eighteen-eighties through 1996, included extensive medical experimentation on Indigenous children. Including the malnutrition experiments documented in detail by historian Ian Mosby in the 2010s. Forced sterilization of Indigenous women, particularly in the sixties and seventies, documented in detail and the subject of ongoing class-action litigation. The contemporary work of decolonizing Canadian health research, including O C A P and T C P S two Chapter Nine, is partly a response to this history.

**Sarah:** And the contemporary S T I epidemiology.

**Kiffer:** Several active challenges in Canada. Chlamydia is the most reported reportable infection. Annual case counts continue to rise. Gonorrhea cases have risen substantially since the early twenty-tens. Emergence of antibiotic-resistant strains that are increasingly difficult to treat. The W H O has classified gonorrhea among its priority pathogens for antibiotic development. Syphilis, after decades of decline, has rebounded dramatically across Canada since approximately 2015. Congenital syphilis has appeared in jurisdictions that hadn't seen cases in a generation. Connected to the opioid crisis, housing instability, and gaps in primary care access for marginalized populations. H I V transmission rates are stable but the disease persists.

**Sarah:** And the response combines several strategies.

**Kiffer:** P r E P — pre-exposure prophylaxis — for H I V. Daily oral antiretroviral medication that prevents H I V infection in people at risk. Available since 2012. Substantially reduced transmission in populations with adequate uptake. U equals U messaging has reduced stigma around H I V diagnosis and improved treatment uptake. H P V vaccination, introduced from 2008 onward, is driving substantial declines in cervical cancer and is increasingly being extended to males. Routine S T I testing in primary care and sexual health clinics has expanded. Comprehensive sexuality education in schools, which has well-documented effects on S T I rates and teen pregnancy, remains politically contested in some Canadian jurisdictions.

**Sarah:** Okay. Section four. H I V slash AIDS. When activism reshaped science. We covered this briefly last lesson — let's go deeper.

**Kiffer:** Right. The first cases reported by the C D C's M M W R on June fifth 1981. Five cases of Pneumocystis carinii pneumonia in previously healthy gay men in Los Angeles. The M M W R report was three pages and easy to overlook. It was nonetheless one of the most consequential single publications in the history of public health.

**Sarah:** And the early naming was charged.

**Kiffer:** Briefly labeled G R I D, gay-related immune deficiency, in 1982. Reflecting both the demographic concentration of early cases and the assumption that the cause was somehow linked to gay male sexual behavior. The label was changed to AIDS, Acquired Immunodeficiency Syndrome, in mid-1982 as broader case-finding showed the syndrome affected diverse populations. The terminology shift reflected the recognition that this was a population-wide infectious disease, not a, quote, gay disease. Though that framing persisted in public discourse for years and contributed to political neglect.

**Sarah:** And the identification of the virus.

**Kiffer:** 1983 to '84. Groups led by Luc Montagnier at the Pasteur Institute in Paris and Robert Gallo at the U S National Cancer Institute. A long-running priority dispute eventually resolved by sharing credit. Montagnier received the 2008 Nobel Prize alongside Françoise Barré-Sinoussi. Diagnostic tests became available in 1985. Blood supply screening was implemented from 1985.

**Sarah:** And the political and social response was disastrously slow.

**Kiffer:** President Reagan didn't publicly speak the word AIDS until 1985. Four years and tens of thousands of deaths into the pandemic. Federal funding for AIDS research and treatment lagged behind the scale of the crisis. The dominant cultural narrative often blamed the affected populations for their own infections. The combination of political neglect and active stigma cost lives that an earlier, more vigorous response could have saved.

**Sarah:** And the first decade and a half was brutal.

**Kiffer:** 1981 to 1996. Extraordinarily high mortality. Limited treatment. Average time from H I V infection to death without treatment about ten to twelve years. For those who developed AIDS-defining illnesses, life expectancy typically one to three years. The eighties and early nineties gay communities in major North American cities lost a generation of men. Hemophiliac communities lost a substantial fraction of their members. Injection drug users were dying in numbers often invisible to mainstream media coverage.

**Sarah:** A Z T was the first antiretroviral.

**Kiffer:** Azidothymidine. Approved by the F D A in March 1987. At the time, the fastest F D A approval in history. Extended survival modestly. Was used as monotherapy, which produced rapid emergence of resistant virus. Subsequent drugs developed through the early nineties faced similar resistance problems when used alone. Combination therapy with two drugs improved on monotherapy but was still inadequate to durably suppress the virus.

**Sarah:** Then the 1996 transformation.

**Kiffer:** Highly active antiretroviral therapy. H A A R T. Combinations of three or more antiretroviral drugs from different classes. Achieved durable viral suppression in most patients and prevented the emergence of resistance through evolutionary mechanisms. The virus would have to acquire multiple resistance mutations simultaneously, which is much less likely than acquiring one. The clinical effect was immediate and dramatic. AIDS-related deaths in industrialized countries dropped by sixty to eighty percent within three years of H A A R T introduction. People with H I V who responded to H A A R T went from preparing to die to planning long lives.

**Sarah:** And the shift was driven in substantial part by activists.

**Kiffer:** That's the part I want to dwell on. The shift from monotherapy to combination therapy was driven in substantial part by activist pressure on regulatory agencies and the research establishment. The conference culture of H I V research — large international meetings that bring researchers, clinicians, activists, and patients together — was unprecedented at the time. Has now been emulated in many other diseases.

**Sarah:** ACT UP.

**Kiffer:** AIDS Coalition to Unleash Power. Founded in March 1987 in New York City. The playwright Larry Kramer was one of the convening figures. ACT UP was a direct-action activist organization whose tactics — protest, civil disobedience, public confrontation of researchers and policymakers — were initially controversial within the medical establishment and have become foundational to the modern patient-advocacy movement.

**Sarah:** What did they actually accomplish?

**Kiffer:** Several specific reforms that have outlasted the campaigns that won them. Faster F D A drug approval. The accelerated approval pathway, used since for many oncology drugs, traces partly to ACT UP pressure. Patient and community representation on research review committees. Now standard in many federal research advisory structures. Broader inclusion criteria for clinical trials. Early H I V trials had excluded women, injection drug users, and people with hepatitis C — populations bearing substantial H I V burden. ACT UP pushed for inclusion. Compassionate-use access to investigational therapies. Now codified in expanded-access programs. And treatment-access pricing. Lower-cost generic antiretroviral programs that have made H A A R T available in low-income countries were partly the consequence of ACT UP campaigns against pharmaceutical pricing.

**Sarah:** And the phrase that came out of this era.

**Kiffer:** Nothing about us without us. Borrowed from disability rights, elevated by ACT UP into a research-ethics principle. Now standard in patient-oriented research broadly. The contemporary structure of community-based participatory research owes its character to the ACT UP era. C I H R's Strategy for Patient-Oriented Research, S P O R, launched in 2011, and analogous structures elsewhere all trace lineage to H I V-era community-driven research practices.

**Sarah:** And then U equals U.

**Kiffer:** By 2008 the Swiss Federal Commission for H I V slash AIDS could announce — and by 2016 this was global consensus — that U equals U. A person with H I V on effective treatment, with sustained undetectable viral load, does not transmit H I V sexually. Reframed the disease entirely. Reduced stigma. Improved treatment uptake. H I V is now in countries with adequate treatment access a chronic manageable condition with near-normal life expectancy.

**Sarah:** And the contemporary H I V epidemiology.

**Kiffer:** P r E P uptake in populations at risk has substantially reduced transmission where it's adequately available. New diagnoses globally are still well above what they could be — UN-AIDS targets a ninety-five percent treated and undetectable population, which remains aspirational in many countries. Persistent inequities. People in low-income countries still face access barriers. Indigenous communities in Canada in some regions still see elevated transmission. The treatment-as-prevention paradigm has shifted what was possible, but the political and economic conditions to deliver it at scale are the limiting constraint.

**Sarah:** And one final note. The cultural style of ACT UP has been controversial.

**Kiffer:** Confrontational. Theatrical. Willing to embarrass powerful institutions publicly. Subsequent patient-advocacy movements in other diseases have generally adopted more cooperative approaches with established institutions. Whether that represents progress or capture is honestly contested. The HIV-era model gave activists genuine power. Cooperative models give activists a seat at the table without the same leverage. The trade-off is real.

**Sarah:** Let me try to pull this together. Eight takeaways.

**Kiffer:** Go.

**Sarah:** First. Maternal mortality in industrialized countries fell roughly a hundred-fold across the twentieth century. The combination of antisepsis, antibiotics, blood transfusion, anaesthesia, prenatal care, and skilled birth attendance produced one of public health's largest achievements. And globally the work is incomplete.

**Kiffer:** Second. The U S maternal mortality paradox — rising rates in the twenty-first century, unique among high-income countries — is real. Black women carry three times the mortality of white women. Indigenous women in Canada twice the mortality of non-Indigenous women. Structural racism in healthcare is the most consistent explanation.

**Sarah:** Third. Margaret Sanger transformed reproductive health and helped make contraception a public good. She also expressed eugenic views that were harmful in their implications. Both are true. Holding both is part of honest history.

**Kiffer:** Fourth. The Pill, approved in 1960, produced one of the most documented social transformations of the twentieth century. Goldin and Katz's work showed Pill access caused substantial increases in women's education, labor force participation, and economic opportunity. Those are health outcomes, not just social ones.

**Sarah:** Fifth. The Tuskegee Syphilis Study ran from 1932 to 1972. Forty years. Twenty-five of them after penicillin became the standard of care. It was conducted by a respectable federal agency, by well-credentialed scientists, with the knowledge of hundreds of physicians and public health officials. Its exposure produced the Belmont Report, the I R B and R E B systems, and the modern research ethics framework. The downstream effects on Black communities' trust in medical institutions are still consequential.

**Kiffer:** Sixth. The modern research ethics infrastructure prevents Tuskegee-style studies but doesn't fully address contemporary challenges. Research on vulnerable populations in low-income countries. Pharmaceutical industry trials with restrictive comparator arms. Research on prisoners and people experiencing homelessness. Administrative data use without community consultation. Vigilance has to be ongoing.

**Sarah:** Seventh. H I V slash AIDS is the most consequential infectious-disease story of the late twentieth century. From its 1981 emergence through the catastrophic decade, to H A A R T in 1996, to U equals U today. The trajectory is biological and biomedical, but the engine of change was substantially activist. ACT UP reshaped F D A regulation, clinical trial inclusion, patient representation on review committees, and pharmaceutical pricing.

**Kiffer:** And eighth. Sexual and reproductive health is the field where public health most directly meets politics, religion, gender, and human rights. The science doesn't sit in a neutral space. A careful contemporary public health practitioner needs to know the science, the history, and the political context simultaneously.

**Sarah:** And the capstone milestone this week — students take their topic and identify its sexual or reproductive dimensions, if any, and its ethical history.

**Kiffer:** What's the ethical history connected to your topic? Has it been the subject of exploitative or unethical research? Has the affected community had voice in shaping how it's studied? That's Week Five.

**Sarah:** Next lesson we move to human development and the life course. The arc from preconception through to old age. That's Lesson 6.

**Kiffer:** Read the module. Bring questions to class.

**Sarah:** Thanks for listening. See you in Lesson 6.

**Kiffer:** Take care of yourselves. See you in class.